CIK 0001410098
- Non-accelerated filer
CorMedix Inc.
Sign in to watch- Ticker
- CRMD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 908-517-9500
- Business address
- 389 INTERPACE PKWY, SUITE 450, PARSIPPANY, NJ, 07054
- Open-market buys, last 90 days
- $391,200
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$391,200. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-12-27 | Kaplan Myron Director | Gift | −5,000 | 140,034 | ||
| 2021-12-06 | David Matthew T Interim CEO and CFO | Purchase | +1,000 | $4.50 | $5K | 3,150 |
| 2021-12-06 | David Matthew T Interim CEO and CFO | Purchase | +1,000 | $4.50 | $5K | 3,150 |
| 2021-11-17 | David Matthew T Interim CEO and CFO | Purchase | +1,000 | $5.07 | $5K | 2,150 |
| 2021-11-16 | Kaplan Myron Director | Purchase | +10,000 | $5.14 | $51K | 175,034 |
| 2021-11-01 | David Matthew T Interim CEO and CFO | Grant or award · Stock Option (Right to Buy Common Stock) | +125,000 | 125,000 | ||
| 2021-11-01 | Mounts Phoebe General Counsel | Grant or award · Stock Option (Right to Buy Common Stock) | +0 | 100,000 | ||
| 2021-05-21 | Masson-Hurlburt Elizabeth EVP, Head of Clinical Ops | Sale | −8,000 | $6.92 | $55K | 0 |
| 2021-05-17 | Kaplan Myron Director | Purchase | +15,000 | $6.03 | $90K | 165,034 |
| 2021-05-13 | Nusbickel Thomas EVP, Chief Commercial Officer | Grant or award · Stock Option (Right to Buy Common Stock) | +260,000 | 260,000 | ||
| 2021-05-13 | Nusbickel Thomas EVP, Chief Commercial Officer | Grant or award · Stock Option (Right to Buy Common Stock) | +7,500 | 7,500 | ||
| 2021-01-11 | ARMSTRONG JR. JOHN L. Exec VP of Tech Operations | Grant or award · Stock Option (Right to Buy Common Stock) | +140,000 | 140,000 | ||
| 2021-01-11 | Masson-Hurlburt Elizabeth EVP, Head of Clinical Ops. | Grant or award · Stock Option (Right to Buy Common Stock) | +140,000 | 140,000 | ||
| 2021-01-11 | DUNTON ALAN W Director | Grant or award · Stock Option (Right to Buy Common Stock) | +30,000 | 30,000 | ||
| 2021-01-11 | Lefkowitz Steven W Director | Grant or award · Stock Option (Right to Buy Common Stock) | +30,000 | 30,000 | ||
| 2021-01-11 | Kaplan Myron Director | Grant or award · Stock Option (Right to Buy Common Stock) | +30,000 | 30,000 | ||
| 2021-01-11 | Duncan Gregory Scott Director | Grant or award · Stock Option (Right to Buy Common Stock) | +20,000 | 20,000 | ||
| 2021-01-11 | Dillione Janet Director | Grant or award · Stock Option (Right to Buy Common Stock) | +30,000 | 30,000 | ||
| 2021-01-11 | Costa Paulo F Director | Grant or award · Stock Option (Right to Buy Common Stock) | +20,000 | 20,000 | ||
| 2021-01-11 | Baluch Khoso Chief Executive Officer | Grant or award · Stock Option (Right to Buy Common Stock) | +320,000 | 320,000 |
Page 11 of 16 · 301 trades